SAS Finds 500+ Leaders Eye Quantum AI for ROI

Key Takeaways

• Over 500 global leaders surveyed on quantum AI adoption.
• Practical application uncertainty now tops cost as primary barrier.
• SAS Quantum Lab promises >100× speedup and 99% cost savings.
• Hybrid quantum‑classical approaches highlighted for fraud detection and drug discovery.
• Leaders aim to patent proprietary quantum AI IP before 2030.

Pulse Analysis

Quantum artificial intelligence sits at the intersection of machine‑learning algorithms and emerging quantum processors. While most analysts expected cost to dominate early adoption discussions, SAS’s 2026 survey of more than 500 senior executives shows uncertainty about real‑world use cases now eclipses expense. The shift reflects a maturing market that demands measurable ROI before committing to hardware that is projected to become production‑ready in the early 2030s. Executives are therefore prioritizing proof‑of‑concept projects that can demonstrate tangible benefits rather than speculative experiments. This appetite for validation signals a turning point for venture capital funding in the quantum space.

To bridge that gap, SAS is rolling out SAS Quantum Lab, an add‑on for its Viya analytics suite. The platform lets users run quantum, classical and hybrid workloads side‑by‑side, instantly comparing performance and cost metrics. Early beta tests report speed improvements exceeding 100× and up to 99% reduction in compute spend, while a built‑in virtual tutor accelerates skill development for teams lacking quantum expertise. Enterprises can also integrate the lab with existing data pipelines, ensuring seamless adoption within current workflows. By lowering both financial and technical barriers, the lab aims to turn curiosity into scalable business value.

The survey’s use‑case inventory underscores why executives are eager to secure quantum AI intellectual property. Applications range from fraud detection in financial services and 5G traffic optimization to molecular simulations that could shave years off drug discovery pipelines. Companies that lock in proprietary quantum algorithms early may gain a competitive moat as hardware matures. Analysts predict that early adopters could see revenue uplift as quantum‑enhanced models outperform legacy systems. With SAS’s tooling reducing entry costs, the industry is poised to move from exploratory pilots to production‑grade solutions by the late 2020s, reshaping analytics across sectors.